Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Timothy G. Call

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The care of patients with chronic lymphocytic leukemia (CLL) has changed dramatically during the past decade. This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL. Although clinical staging (Rai and Binet) remains the foundation for determining prognosis, 50% of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL. New laboratory techniques (CD38, fluorescence in situ hybridization [FISH]) can identify some patients with early-stage CLL at high risk of rapid disease progression. The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents, which have culminated in dramatically improved response rates. Supportive care guidelines now include vaccination strategies, surveillance for secondary malignancies, and aggressive management of infectious complications. An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial.

Original languageEnglish (US)
Pages (from-to)388-398
Number of pages11
JournalMayo Clinic Proceedings
Volume79
Issue number3
StatePublished - 2004

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Purine Nucleosides
Lymphocytosis
Premature Mortality
Alkylating Agents
Hematology
Fluorescence In Situ Hybridization
Disease Progression
Patient Care
Vaccination
Referral and Consultation
Monoclonal Antibodies
Clinical Trials
Guidelines
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia. / Shanafelt, Tait D.; Call, Timothy G.

In: Mayo Clinic Proceedings, Vol. 79, No. 3, 2004, p. 388-398.

Research output: Contribution to journalArticle

Shanafelt, Tait D. ; Call, Timothy G. / Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia. In: Mayo Clinic Proceedings. 2004 ; Vol. 79, No. 3. pp. 388-398.
@article{88cc9e843453472db3ba437e203ddb75,
title = "Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia",
abstract = "The care of patients with chronic lymphocytic leukemia (CLL) has changed dramatically during the past decade. This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL. Although clinical staging (Rai and Binet) remains the foundation for determining prognosis, 50{\%} of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL. New laboratory techniques (CD38, fluorescence in situ hybridization [FISH]) can identify some patients with early-stage CLL at high risk of rapid disease progression. The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents, which have culminated in dramatically improved response rates. Supportive care guidelines now include vaccination strategies, surveillance for secondary malignancies, and aggressive management of infectious complications. An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial.",
author = "Shanafelt, {Tait D.} and Call, {Timothy G.}",
year = "2004",
language = "English (US)",
volume = "79",
pages = "388--398",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia

AU - Shanafelt, Tait D.

AU - Call, Timothy G.

PY - 2004

Y1 - 2004

N2 - The care of patients with chronic lymphocytic leukemia (CLL) has changed dramatically during the past decade. This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL. Although clinical staging (Rai and Binet) remains the foundation for determining prognosis, 50% of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL. New laboratory techniques (CD38, fluorescence in situ hybridization [FISH]) can identify some patients with early-stage CLL at high risk of rapid disease progression. The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents, which have culminated in dramatically improved response rates. Supportive care guidelines now include vaccination strategies, surveillance for secondary malignancies, and aggressive management of infectious complications. An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial.

AB - The care of patients with chronic lymphocytic leukemia (CLL) has changed dramatically during the past decade. This review summarizes the work-up of lymphocytosis and the current diagnostic criteria and management of CLL. Although clinical staging (Rai and Binet) remains the foundation for determining prognosis, 50% of patients with early-stage disease at diagnosis will experience an aggressive course of disease with early progression and premature death due to CLL. New laboratory techniques (CD38, fluorescence in situ hybridization [FISH]) can identify some patients with early-stage CLL at high risk of rapid disease progression. The array of treatment options has expanded in recent years and now includes monoclonal antibodies used alone or in combination with purine nucleoside analogues and alkylating agents, which have culminated in dramatically improved response rates. Supportive care guidelines now include vaccination strategies, surveillance for secondary malignancies, and aggressive management of infectious complications. An early hematology consultation is recommended for all patients at diagnosis to identify and counsel high-risk patients with early-stage disease who may benefit from more frequent follow-up or early treatment as part of a clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=1442306830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442306830&partnerID=8YFLogxK

M3 - Article

C2 - 15008611

AN - SCOPUS:1442306830

VL - 79

SP - 388

EP - 398

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -